Treatment with Uplizna (inebilizumab-cdon) effectively prevented disease attacks and disability worsening for Asian people with neuromyelitis optica spectrum…
Articles by Marisa Wexler, MS
A Phase 2 clinical trial is testing InnoCare Pharma’s experimental oral medication orelabrutinib in people with neuromyelitis optica…
A history of smoking is associated with poorer recovery from disease relapses in people with neuromyelitis optica spectrum disorder…
When the immune system launches an attack to fight off a cytomegalovirus infection, immune cells may accidentally target aquaporin-4 (AQP4),…
Older age, a poor response to steroids, and the need for a blood-cleaning procedure known as plasma exchange all were…
An international team of experts has published evidence-based recommendations for how to best treat people with neuromyelitis optica spectrum…
Eating more oily fish and raw vegetables may decrease a person’s risk of developing neuromyelitis optica spectrum disorder (NMOSD),…
Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum…
Ultomiris (ravulizumab) has been approved by the European Commission to treat adults with neuromyelitis optica spectrum disorder (NMOSD)…
Antibodies against aquaporin-4 (AQP4) are detectable in the blood several years before symptoms occur in most people with neuromyelitis…